GALDERMA GROUP AG (GALDY) AI Stock Analysis

Galderma Group AG operates as a dermatology company worldwide. Founded in 1981 and headquartered in Zug, Switzerland, the company delivers a science-based portfolio of brands and services across injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its flagship brand portfolio includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl. The organization employed 7,676 people as of the latest reporting.

Galderma expanded revenue from $3.44B in FY2021 to $5.24B in FY2025, reflecting an 11.1% 4-year CAGR. Revenue growth accelerated to 18.0% in FY2025 following gains of 11.0% in FY2022, 7.7% in FY2023, and 7.8% in FY2024. Profitability transitioned from net losses of -$154.3M in FY2021, -$98.5M in FY2022, and -$57.0M in FY2023 to positive net income of $231.0M in FY2024 and $613.0M in FY2025. Gross margin was 68.9% in FY2025, while operating margin expanded to 16.7%. For the trailing twelve months ended December 31, 2025, revenue reached $5.92B, with quarterly revenue growing 27.7% and quarterly earnings advancing 130.7% year-over-year.

As of December 31, 2025, Galderma held $780.0M in cash and short-term investments alongside $2.58B in total debt, leaving net debt at $1.80B. Shareholders' equity was $8.15B against total assets of $13.39B, yielding a debt-to-equity ratio of 0.32 and a current ratio of 1.19. In FY2025, operating cash flow stood at $1.19B and free cash flow reached $1.03B. Cash deployment in FY2025 included $154.0M in capital expenditures, $363.0M for share buybacks, and $41.0M in dividends paid.

GALDY closed at $42.47 on October 16, 2026, delivering a 1-year return of 22.9% compared to 16.8% for the S&P 500 (SPY). The company carries a market capitalization of $49.52B and an enterprise value of $47.58B. It trades at a trailing P/E of 58.2x, a forward P/E of 29.9x, and an EV/EBITDA of 33.4x, which compare to the median of its US-listed Healthcare peers of 24.6x trailing P/E, 17.3x forward P/E, and 12.0x EV/EBITDA. Its price-to-sales ratio is 8.4x versus the peer median of 4.1x, while its PEG ratio stands at 1.17.

GALDY offers an annual forward dividend of $0.09 per share, equating to a dividend yield of 0.21%. The dividend payout ratio is 12.1%, and dividends have been paid for 2 consecutive years. The last ex-dividend date was April 27, 2026.

One analyst covers the stock, issuing 1 Strong Buy rating with no Buy, Hold, Sell, or Strong Sell recommendations. The mean price target is $50.08, representing a 17.9% premium over the last close of $42.47. For the fiscal year ending December 31, 2026, the consensus expects EPS of $3.51 on revenue of $6.42B. Projections for the next fiscal year forecast EPS of $5.16 and revenue of $7.54B, representing growth of 47.2% and 17.9%, respectively.

This page is an AI-written research summary of GALDERMA GROUP AG (GALDY). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: GALDY income statement, GALDY balance sheet, GALDY key metrics, GALDY analyst forecast, GALDY chart. See the GALDY stock overview for the latest quote and news.